Like a middle school teacher repeatedly reminding students that a big paper is due, the US FDA continues to prompt drug sponsors to submit a mandatory one-time report on marketed products.
As part of the 2017 FDA Reauthorization Act, sponsors must submit a one-time update of the marketing status for all...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?